热门资讯> 正文
iBio放弃了拟议的公开募股
2025-08-19 04:12
- iBio(IBIO) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- iBio (NASDAQ:IBIO) said on Monday that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of iBio’s common stock, and (ii) accompanying Series G warrants and Series H warrants each representing the right to purchase a fraction of a share of iBio’s common stock.
- All of the securities to be sold in the proposed offering will be offered by iBio.
- iBio intends to use the net proceeds received from the offering to advance its preclinical cardiometabolic programs, and the balance, if any, to fund iBio’s working capital requirements and for other general corporate purposes.
- iBio (NASDAQ:IBIO) shares were down more than 13% in extended trading.
More on iBio
- Seeking Alpha’s Quant Rating on iBio
- Historical earnings data for iBio
- Financial information for iBio
推荐文章
一周IPO丨双登股份下周上市，超额认购逾3000倍；佳鑫国际资源火热招股中
一周财经日历 | 超重磅！英伟达、阿里、拼多多财报轮番；美国7月PCE数据来袭
美股机会日报 | 倒计时开始！市场屏息以待鲍威尔讲话；中概股名创优品涨超8%，拼多多涨超4%
AH股追踪丨上证指数一举突破3800点！中芯国际A股飙涨14%，H股涨逾9%
港股异动 | 中兴通讯H股午后持续拉升！盘中涨超13%创历史新高
华盛早报 | 韩国股民疯买港股，外资传大消息，做多中国热情持续攀升；标普“五连阴”！今晚华尔街枕戈以待
美股机会日报 | 关税税率最高15%！美欧敲定框架贸易协议；何小鹏增持310万股，小鹏汽车盘前股价涨超5%
一图看懂 | 哔哩哔哩Q2营收73亿元！上半年手游收入大增68%，经调净利润同比扭亏为盈5.6亿元
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
